Table 1.

Recommendations on discontinuation of antiviral therapy in chronic hepatitis B patients by the European Association for the Study of Liver, American Association for the Study of Liver, and Asian Pacific Association for the Study of Liver guidelines

	HBeAg-positive	HBeAg-negative	Cirrhosis
EASL (2017)	HBsAg seroclearance	HBsAg seroclearance	No recommendation until HBsAg loss
	HBeAg seroconversion and HBV DNA undetectable with at least 12 mo of consolidation therapy	May be consider before HBsAg loss if undetectable HBV DNA for at least 3 yr (close monitoring for at least 1 yr)
AASLD (2018)	HBsAg seroclearance	HBsAg seroclearance (close monitoring every 3 mo for at least 1 yr)	No recommendation until HBsAg loss
	HBeAg seroconversion with at least 12 mo of persistent ALT levels and undetectable HBV DNA (close monitoring every 3 mo for at least 1 yr)	May be consider if there is a compelling rationale and under careful monitoring every 3 mo for at least 1 yr
APASL (2015)	HBeAg seroconversion with undetectable HBV DNA and persistently normal ALT levels with at least 1 yr of consolidation therapy (preferably 3 yr)	HBsAg seroclearance with anti-HBs seroconversion or at least 12 mo of a post-HBsAg clearance consolidation period	May be consider before HBsAg loss if disease is compensated and under a careful monitoring plan
		-After treatment for at least 2 yr with undetectable HBV DNA documented on 3 separate occasions, 6 mo apart

AALSD: American Association for the Study of Liver; APASL: Asian Pacific Association for the Study of Liver; EASL: European Association for the Study of Liver; HBeAg: Hepatitis B e antigen.